drugset / Trial / NCT00813709

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

NCT00813709 ↗

Phase 3 Completed 402 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupDouble-blindTreatment

Summary

REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum \[FBS\]-free/human serum albumin \[HSA\]-free formulation of interferon \[IFN\]-beta-1a (RNF).

Timeline

Start
2008-12
Primary completion
2011-08
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator RNF Unknown 44 ug Subcutaneous

Indications